Risk Stratification: The Five-Factor Score
At a Glance
The Five-Factor Score (FFS) is a tool rheumatologists use to determine the severity of Polyarteritis nodosa (PAN). It evaluates kidney, gut, heart, and nervous system involvement, plus age. A score of 0 suggests milder disease, while 1 or higher indicates a need for more aggressive treatment.
When you are diagnosed with a complex disease like Polyarteritis nodosa (PAN), your medical team needs a reliable way to determine how aggressively to treat the condition. To do this, rheumatologists use a standardized tool called the Five-Factor Score (FFS) [1][2]. This score helps your doctor estimate the severity of your disease, assess the risk of major complications, and tailor your medication plan accordingly [3][4].
What the FFS Measures
The FFS looks at five specific clinical markers that indicate how deeply the vasculitis is affecting your body’s vital systems [3]. While there are two versions of this score (the original 1996 version and a revised 2009 version), they both focus on similar high-risk indicators [1][5]:
- Kidney Function: High levels of creatinine (a waste product) in your blood or significant amounts of protein in your urine suggest that the arteries supplying your kidneys are inflamed [3][6].
- Gastrointestinal (GI) Involvement: This is one of the most critical factors. Doctors look for signs of severe abdominal pain or bleeding in the gut [7][6].
- Cardiac Involvement: Inflammation that affects the heart muscle (cardiomyopathy) or the arteries supplying the heart is a sign of severe disease [3].
- Age: In the modern 2009 version of the score, being over the age of 65 is considered an independent risk factor [4].
- Central Nervous System Involvement: The 1996 FFS version specifically evaluates whether the vasculitis is affecting the brain or spinal cord [8]. (Unlike other vasculitides, PAN typically does not involve the lungs).
How the Score Guides Your Treatment
The FFS is not just a number; it acts as a “green light” or “red light” for specific therapies [3].
- FFS = 0: This generally indicates a lower risk of severe organ complications. In these cases, doctors may start with corticosteroids (steroids) alone to see if the disease can be controlled without more powerful drugs [3].
- FFS ≥ 1: A score of 1 or higher signals “severe” disease [4]. This usually prompts doctors to add a second, more intensive medication—often cyclophosphamide—to your initial treatment plan to aggressively protect your organs from damage [3][4].
Understanding the Risks
It is important to know the potential risks of untreated systemic PAN, while remembering that these complications are exactly what your medical team is working rapidly to prevent [9]. The most serious risks include mesenteric ischemia (a lack of blood flow to the intestines) and, in extreme cases, bowel perforation (a hole in the wall of the gut) [7][10].
By calculating the FFS early in your diagnosis, your doctors can identify if you are at risk for these severe complications and start the aggressive treatment necessary to halt the vasculitis before it progresses [11][12]. Modern medicine is highly effective at stopping this damage in its tracks when applied promptly.
Common questions in this guide
What is the Five-Factor Score for Polyarteritis nodosa?
What does a Five-Factor Score of 0 mean for my treatment?
What happens if my Five-Factor Score is 1 or higher?
Why is gastrointestinal involvement an important factor in PAN?
How does my age affect my Five-Factor Score?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.What is my current Five-Factor Score (FFS), and how does it affect the intensity of my treatment?
- 2.Do I have any signs of kidney involvement, such as high creatinine or protein in my urine, that contribute to my risk score?
- 3.Are my stomach pains a sign of gastrointestinal involvement, and if so, how does that change my disease severity?
- 4.Given my age and health history, do you consider my PAN to be 'high-risk' based on the FFS variables?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
References
References (12)
- 1
Association of five-factor score with the mortality in Japanese patients with polyarteritis nodosa.
Abe Y, Tada K, Yamaji K, et al.
Modern rheumatology 2018; (28(2)):308-312 doi:10.1080/14397595.2017.1337265.
PMID: 28648103 - 2
The clinical characteristics and treatment outcomes of patients with systemic polyarteritis nodosa: a single-centre study from India.
Jha A, R C, Yadav B, et al.
Rheumatology (Oxford, England) 2025; (64(6)):3710-3717 doi:10.1093/rheumatology/keaf014.
PMID: 39799509 - 3
Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss).
Nguyen Y, Guillevin L
Seminars in respiratory and critical care medicine 2018; (39(4)):471-481 doi:10.1055/s-0038-1669454.
PMID: 30404114 - 4
Treatment of systemic necrotizing vasculitides in patients aged sixty-five years or older: results of a multicenter, open-label, randomized controlled trial of corticosteroid and cyclophosphamide-based induction therapy.
Pagnoux C, Quéméneur T, Ninet J, et al.
Arthritis & rheumatology (Hoboken, N.J.) 2015; (67(4)):1117-27 doi:10.1002/art.39011.
PMID: 25693055 - 5
Predictive factors for mortality in elderly Japanese patients with severe microscopic polyangiitis: A retrospective single-center study.
Abe Y, Tamura N, Yang KS, et al.
Modern rheumatology 2017; (27(2)):315-319 doi:10.1080/14397595.2016.1205778.
PMID: 27400379 - 6
Spontaneous accessory renal artery aneurysm rupture as a first presentation of polyarteritis nodosa: a case report and review of literature.
Amro RN, Maraqa L, Abo Jheasha AA, et al.
Annals of medicine and surgery (2012) 2025; (87(6)):3956-3962 doi:10.1097/MS9.0000000000003331.
PMID: 40486591 - 7
Polyarteritis nodosa complicated by renal aneurysm and intestinal perforation: A case report.
Ma Y, Luan L, Zhang J, et al.
Medicine 2024; (103(34)):e39445 doi:10.1097/MD.0000000000039445.
PMID: 39183419 - 8
Successful Treatment of Polyarteritis Nodosa With Multifocal Intracranial and Mesenteric Stenoses Using Endovascular Stenting and Tocilizumab.
Nobre M, Carrilho M, Dias A, et al.
Cureus 2025; (17(8)):e89607 doi:10.7759/cureus.89607.
PMID: 40922821 - 9
Wunderlich's syndrome as a manifestation of polyarteritis nodosa.
Beirão P, Teixeira L, Pereira P, Coelho ML
BMJ case reports 2017; (2017()) doi:10.1136/bcr-2016-218478.
PMID: 28137905 - 10
Successful surgical intervention for rectal perforation due to polyarteritis nodosa: report of a case.
Yoshiya K, Imamura Y, Nakaji Y, et al.
Surgical case reports 2017; (3(1)):43 doi:10.1186/s40792-017-0316-0.
PMID: 28290145 - 11
The "Viral" Form of Polyarteritis Nodosa (PAN)-A Distinct Entity: A Case Based Review.
Pașa V, Popa E, Poroch M, et al.
Medicina (Kaunas, Lithuania) 2023; (59(6)) doi:10.3390/medicina59061162.
PMID: 37374366 - 12
Complex presentation of polyarteritis nodosa: Renal pseudoaneurysm rupture and bowel ischemia: A case report.
Rabaya AF, Ibraheem K, Shawer O, et al.
International journal of surgery case reports 2025; (129()):111172 doi:10.1016/j.ijscr.2025.111172.
PMID: 40117834
This page explains the Five-Factor Score for Polyarteritis nodosa for educational purposes. Always consult your rheumatologist to understand your specific disease risk and personalized treatment plan.
Get notified when new evidence is published on Polyarteritis nodosa.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.